T
Thomas Frandsen
Researcher at Copenhagen University Hospital
Publications - 116
Citations - 4250
Thomas Frandsen is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Cancer & Asparaginase. The author has an hindex of 29, co-authored 111 publications receiving 3438 citations. Previous affiliations of Thomas Frandsen include Finsen Laboratory & Georgetown University.
Papers
More filters
Journal ArticleDOI
The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies
Khalid Bajou,Véronique Masson,Robert D. Gerard,Petra M. Schmitt,Valerie Albert,M Praus,Leif R. Lund,Thomas Frandsen,Nils Brünner,Keld Danø,Norbert E. Fusenig,Ulrich H. Weidle,Geert Carmeliet,David J. Loskutoff,Desire Collen,Peter Carmeliet,Jean-Michel Foidart,Agnès Noël +17 more
TL;DR: It is observed that PAI-1 promoted tumor angiogenesis, not by interacting with VN, but rather by inhibiting proteolytic activity, suggesting that excessive plasmin proteolysis prevents assembly of tumor vessels.
Journal ArticleDOI
Functional overlap between two classes of matrix‐degrading proteases in wound healing
Leif R. Lund,John Rømer,Thomas H. Bugge,Boye Schnack Nielsen,Thomas Frandsen,Jay L. Degen,Ross W. Stephens,Keld Danø +7 more
TL;DR: The results predict that complete arrest of this latter process in therapeutic settings will require the use of inhibitors of both classes of proteases, probably in the dissection of the fibrin‐rich provisional matrix by migrating keratinocytes.
Journal ArticleDOI
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
Nina Toft,Nina Toft,Henrik Birgens,Jonas Abrahamsson,Laimonas Griskevicius,Helene Hallböök,Mats Heyman,Tobias Wirenfeldt Klausen,Olafur G. Jonsson,K. Palk,Kaie Pruunsild,Petter Quist-Paulsen,Goda Vaitkeviciene,Kim Vettenranta,Ann Åsberg,Thomas Frandsen,Hanne Vibeke Marquart,Hans O. Madsen,Ulrika Norén-Nyström,Kjeld Schmiegelow +19 more
TL;DR: A pediatric-based protocol is tolerable and effective for young adults, despite their increased frequency of higher risk features, with significant differences only for non-high risk groups.
MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780
Nils Brünner,Thomas Frandsen,Thomas Frandsen,Claus Holst-Hansen,Mian Bei,Erik W. Thompson,Alan E. Wakeling,Marc E. Lippman,Robert Clarke +8 more
TL;DR: The data suggest that some breast cancer patients who acquire resistance to tamoxifen may not develop cross-resistance to treatment with steroidal antiestrogens.
Journal Article
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Nils Brünner,Nils Brünner,Birgitte Boysen,Stana Jirus,Todd C. Skaar,Claus Holst-Hansen,Jeremy Lippman,Thomas Frandsen,Mogens Spang-Thomsen,Suzanne A. W. Fuqua,Robert Clarke +10 more
TL;DR: If this pattern of cross-resistance occurs in some breast cancer patients, administering triphenylethylene antiestrogens as a first-line therapy with a cross-over to steroidal compounds upon recurrence may be advantageous.